The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 245, Issue 5, 2007, Pages 725-732

  Mathalone, Nurit ^a   Lahat, Nitza ^a,b   Rahat, Michal A ^b   Bahar Shany, Keren ^c   Oron, Yoram ^c   Geyer, Orna ^a  

^a CARMEL MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Ischemia; MMPs; Retina

Indexed keywords

AMINOGUANIDINE; EOSIN; GELATINASE A; GELATINASE B; HEMATOXYLIN; MATRIX METALLOPROTEINASE; MINOCYCLINE; N NITROARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; PROGELATINASE A; PROGELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; HISTOPATHOLOGY; IN VITRO STUDY; INTRAOCULAR HYPERTENSION; MALE; MORPHOMETRICS; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA GANGLION CELL; RETINA INJURY; RETINA ISCHEMIA; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GUANIDINES; ISCHEMIA; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MINOCYCLINE; NITRIC OXIDE SYNTHASE; NITROARGININE; RATS; RATS, SPRAGUE-DAWLEY; RETINAL DISEASES; RETINAL VESSELS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 34250713516     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-006-0362-y     Document Type: Article

References (46)

1. Adachi K, Fujita Y, Morizane C, Akaike A, Ueda M, Satoh M, Masai H, Kashii S, Honda Y (1998) Inhibition of NMDA receptors and nitric oxide synthase reduces ischemic injury of the retina. Eur J Pharmacol 350:53-57
2. Baptiste DC, Hartwick AT, Jollimore CA, Baldridge WH, Seigel GM, Kelly ME (2004) An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. Mol Pharmacol 66:1113-1122
3. Belayev L, Busto R, Zhao W, Ginsberg MD (1996) Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res 739:88-96
4. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW (2002) Targeting leukocyte MMPs and transmigration: Minocycline as a potent therapy for multiple sclerosis. Brain 125:1297-1308
5. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM (2000) Minocycline inhibits caspase-1 and caspase -3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797-801
6. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schultz R (2000) Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101:1833-1839
7. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR (1997) Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 238:53-56
8. Cursio R, Mari B, Louis K, Rostagno P, Saint-Paul MC, Giudicelli J, Bottero V, Anglard P, Yiotakis A, Dive V, Gugenheim J, Auberger P (2002) Rat liver injury after nonthermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor. FASEB J 16:93-95
9. D'Amore PA (1994) Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 35:3974-3979
10. Das A, McLamore A, Song W, Mcguire PG (1999) Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 117:498-503
11. Duivenvoorden WC, Hirte HW, Singh G (1997) Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invasion Metastasis 17:312-322
12. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PH (1999) Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 842:92-100
13. Gasche Y, Fujimura M, Morita-Fujimura Y, Copin JC, Kawase M, Massengale J, Chan PH (1999) Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: A possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 19:1020-1028
14. Geyer O, Almog J, Lupu-Meiri M, Lazar M, Oron Y (1995) Nitric oxide synthase inhibitors protect rat retina against ischemic injury. FEBS Lett 374:399-402
15. Hangai M, Miyamoto K, Hiroi K, Tujikawa A, Ogura Y, Honda Y, Yoshimura N (1999) Roles of constitutive nitric oxide synthase in postischemia rat retina. Invest Ophthalmol Vis Sci 40:450-458
16. Horton WE Jr, Udo I, Precht P, Balakir R, Hasty K (1998) Cytokine inducible matrix metalloproteinase expression in immortalized rat chondrocytes is independent of nitric oxide stimulation. In Vitro Cell Dev Biol Anim 34:378-384
17. Jain S, Bicknell GR, Nicholson ML (2000) Molecular changes in extracellular matrix turnover after renal ischaemia-reperfusion injury. Br J Surg 87:1188-1192
18. Jiang X, Namura S, Nagata I (2001) Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci Lett 305:41-44
19. Ju W, Kim K, Park D, Park C, Oh S, Chung J, Chum M (2000) Nitric oxide is involved in sustained and delayed cell death of rat retina following transient ischemia. Brain Res 881:231-236
20. Kosano H, Okano T, Katsura Y, Noritake M, Kado S, Matsuoka T, Nishigori H (1999) ProMMP-9 (92 KDa) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci 64:2307-2315
21. Lahat N, Rahat MA, Brod V, Cohen S, Weber G, Kinarty A, Bitterman H (1999) Abdominal surgery reduces the ability of rat spleen cells to synthesize and secrete active TNF-α by a multilevel regulation. Clin Exp Immunol 115:19-25
22. Ledingham MA, Denison FC, Riley SC, Norman JE (1999) Matrix metalloproteinase-2 and -9 and their inhibitors are produced by the human uterine cervix but their secretion is not regulated by nitric oxide donors. Hum Reprod 14:2089-2096
23. Lin S, Zhang Y, Dodel R, Farlaw MR, Paul SM, Du Y (2001) Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett 315:61-64
24. Lindsey M, Wedin K, Brown MD, Keller C, Evans AJ, Smolen J, Burns AR, Rossen RD, Michael L, Entman M (2001) Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 103:2181-2187
25. Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, Arenillas J, Monasterio J (2001) Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32:2762-2767
26. Noda K, Ishida S, Inoue M, Obata K, Oguchi Y, Okada Y, Ikeda E (2003) Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 44:2163-2170
27. Paemen L, Martens E, Norga K, Masure S, Roets E, Hoogmartens J, Opdenakker G (1996) The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol 52:105-111
28. Parsons SL, Watsom SA, Broen PD, Collins HM, Steele RJC (1997) Matrix metalloproteinases. Br J Surg 84:160-166
29. Planas AM, Sole S, Justicia C (2001) Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 8:834-846
30. Renner O, Tsimpas A, Kostin S, Valable S, Petit E, Schaper W, Marti HH (2003) Time- and cell type-specific induction of platelet-derived growth factor receptor-beta during cerebral ischemia. Brain Res Mol Brain Res 113:44-51
31. Rivera S, Ogier C, Jourquin J, Timsit S, Szklarczyk AW, Miller K, Gearing AJ, Kaczmarek L, Khrestchatisky M (2002) Gelatinase B and TIMP-1 are regulated in a cell- and time-dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia. Eur J Neurosci 15:19-32
32. Rosenberg GA, Estrada EY, Dencoff JE (1998) Matrix metalloproteinases and TIMPs are associated with blood brain barrier opening after reperfusion in rat brain. Stroke 29:2189-2195
33. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG (1992) TIMP-2 reduces proteolytic opening of blood brain barrier by type IV collagenase. Brain Res 576:203-207
34. Rosenberg GA, Navratil M, Barone F, Feuerstein G (1996) Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 16:360-366
35. Ryan ME, Usman A, Ramamurthy NS, Golub LM, Greenwald RA (2001) Excessive matrix metalloproteinase activity in diabetes: Inhibition by tetracycline analogues with zinc reactivity. Curr Med Chem 8:305-316
36. Sadowski T, Steinmeyer J (2001) Effects of tetracyclines on the production of matrix metalloproteinases and plasminogen activators as well as of their natural inhibitors, tissue inhibitor of metalloproteinases-1 and plasminogen activator inhibitor-1. Inflamm Res 50:175-182
37. Spinale FG, Coker ML, Bond BR, Zellner JL (2000) Myocardial matrix degradation and metalloproteinase activation in the failing heart: A potential therapeutic target. Cardiovasc Res 46:225-238
38. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J (2001) Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21:2580-2588
39. Tikka TM, Koistinaho JE (2001) Minocycline provides neuroprotection against N-methyl-d-aspartate neurotoxicity by inhibiting microglia. J Immunol 166:7527-7533
40. Vaday GG, Hershkovitz R, Rahat MA, Lahat N, Cahalon L, Lider O (2000) Fibronectin-bound TNF-α stimulates monocyte matrix metalloproteinase-9 and regulates chemotaxis. J Leukoc Biol 68:737-747
41. Woessner JF (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145-2154
42. Yano M, Omoto Y, Yamakawa Y, Nakashima Y, Kiriyama M, Saito Y, Fujii Y (2001) Increased matrix metalloproteinase 9 activity and mRNA expression in lung ischemia-reperfusion injury. J Heart Lung Transplant 20:679-686
43. Yoo MH, Lee YH, Lee SE, Koh JY, Yoon YH (2004) Protection by pyruvate of rat retinal cells against zinc toxicity in vitro, and pressure-induced ischemia in vivo. Invest Ophthalmol Vis Sci 45:1523-1530
44. Zhang C, Lei B, Lam TT, Yang F, Sinha D, Tso MO (2004) Neuroprotection of photoreceptors by minocycline in light-induced retinal degeneration. Invest Ophthalmol Vis Sci 45:2753-2759
45. Zhang X, Sakamoto T, Hata Y, Kubota T, Hisatomi T, Murata T, Ishibashi T, Inomata H (2002) Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats. Exp Eye Res 74:577-584
46. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Sarang S, Liu AS, Hart DM, Wu du C, Gullans S, Ferrante RJ, Przedborski S, Ktistal BS, Friedlander RM (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417:74-78